An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.
Quiz|Articles|September 27, 2026
Dermatology Times Spot Test: September 27, 2026
Author(s)Shannon Heaning, Content Associate
Listen
0:00 / 0:00
Key Takeaways
- Weekly spot-test format aims to reinforce dermatology fundamentals while integrating evolving evidence and practice patterns.
- This installment concentrates on hidradenitis suppurativa treatment frameworks, including medical, procedural, and emerging approaches.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on hidradenitis suppurativa (HS) management, including biologic treatment, deroofing, and emerging strategies discussed by Alexandra Charrow, MD, FAAD, at Maui Derm NP+PA Fall 2026.
Do you have a set of quiz questions to share? Contact editor Shannon Heaning at Sheaning
According to Alexandra Charrow, MD, FAAD, which clinical findings can help clinicians assess the inflammatory burden of hidradenitis suppurativa when considering escalation to biologic therapy?
What procedural intervention did Charrow encourage dermatology clinicians to become more comfortable incorporating into hidradenitis suppurativa care?
What emerging area of research did Charrow identify as potentially helping clinicians select the most appropriate hidradenitis suppurativa therapy for individual patients?
Advertisement
Related to this article
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
5